Dr. Reddy’s Laboratories’ API manufacturing plant at Srikakulam in state of Andhra Pradesh has been audited by the US Food and Drug Administration (USFDA), and the audit has been completed on April 4, 2017. The company has been issued a Form 483 with 2 observations, which it is addressing.
Earlier, the company’s formulation manufacturing facility at Duvvada, Visakhapatnam, had been audited by the USFDA, and the audit had been completed on March 8, 2017. The company had been issued a Form 483 with 13 observations, which it was addressing.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
